Schering Corporation

Merck Sharp + Dohme Corp.

Julius J Matasi

Deen Tulshian

Lisa S Silverman

Ginny Dai Ho

Francis M Cuss

John A Hey

Ana Bercovici

Richard W Chapman

Robbie L McLeod

Duane A Burnett

Wen-Lian Wu

Thavalakulamgara K Sasikumar

Martin Domalski

Li Qiang

Peter Korakas

John P Caldwell

Bernard R Neustadt

Michael D Altman

Jongwon Lim

Joey Lee Methot

Brian J Lavey

Craig R Gibeau

Gregory Scott Martin

John W Lampe

William Bert Geiss

Michael F Czarniecki

Liang Zhu

Eugenia Y Kiselgof

W Michael Seganish

William T McElroy

Van-Duc Le

Stephanie Brumfield

Stephanie Nicole Cooke

James C Haber, Jr

Stephanie Nicole Brumfield

Deen B Tulshian

John William Lampe

William T Mcelroy

Martin S Domalski

Sasikumar K Thavalakulamgara

This invention relates to aminopyrimidinone compounds of Formula (I) that are inhibitors of Interleukin receptor-associated kinases, in particular IRAK-4, and are useful in the treatment or prevention of inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease.

Aminopyrimidinones as interleukin receptor-associated kinase inhibitors

The present invention relates to Polycyclic Guanine Derivatives, compositions comprising the Polycyclic Guanine Derivatives and methods of using the Polycyclic Guanine Derivatives to treat pain or an inflammatory disease.

Polycyclic guanine derivatives and use thereof

In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J-J, X, and R-Rare as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease. 

mGluR1 antagonists as therapeutic agents

In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J-J, X, and R&#x2014;Rare as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease. 

Novel compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein:

High affinity ligands for nociceptin receptor ORL-1

Disclosed are compounds having the structural formulaor pharmaceutically acceptable salts or solvates thereof, wherein

Adenosine A2a receptor antagonists

Growing community of inventors

Monmouth Junction, NJ, United States of America

Julius J Matasi